Gilead Sciences, Inc. $GILD Shares Sold by Arlington Financial Advisors LLC

Key Points

• Arlington Financial Advisors LLC reduced its holdings in Gilead Sciences by 5.5%, selling 2,552 shares and bringing their total to 43,987 shares, valued at approximately $4.88 million.
• Gilead Sciences recently declared a quarterly dividend of $0.79 per share, offering an annualized yield of 2.7% and maintaining a payout ratio of 62.95%.
• Several analysts raised their price targets for Gilead Sciences, with Rothschild & Co increasing it from $136 to $143, indicating a consensus rating of "Moderate Buy" and an average price target of $118.08.

Arlington Financial Advisors LLC cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.5% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 43,987 shares of the biopharmaceutical company's stock after selling 2,552 shares during the quarter. Arlington Financial Advisors LLC's holdings in Gilead Sciences were worth $4,877,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GILD. Brighton Jones LLC raised its holdings in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Bison Wealth LLC acquired a new position in shares of Gilead Sciences in the fourth quarter worth $215,000. GAMMA Investing LLC raised its holdings in shares of Gilead Sciences by 24.9% in the first quarter. GAMMA Investing LLC now owns 22,760 shares of the biopharmaceutical company's stock worth $2,550,000 after acquiring an additional 4,532 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Gilead Sciences by 4.7% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 292,966 shares of the biopharmaceutical company's stock worth $32,827,000 after acquiring an additional 13,194 shares during the last quarter. Finally, Hanson & Doremus Investment Management raised its holdings in shares of Gilead Sciences by 1,024.6% in the first quarter. Hanson & Doremus Investment Management now owns 2,744 shares of the biopharmaceutical company's stock worth $307,000 after acquiring an additional 2,500 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently weighed in on GILD. Rothschild & Co Redburn boosted their price target on Gilead Sciences from $136.00 to $143.00 and gave the stock a "buy" rating in a report on Friday, September 12th. UBS Group boosted their price target on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target for the company in a report on Tuesday, August 19th. Truist Financial raised Gilead Sciences from a "hold" rating to a "buy" rating and boosted their price target for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Finally, Royal Bank Of Canada boosted their price target on Gilead Sciences from $98.00 to $100.00 and gave the stock a "sector perform" rating in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $118.08.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the business's stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $340,710.00. Following the completion of the sale, the insider owned 113,193 shares of the company's stock, valued at approximately $12,855,329.01. The trade was a 2.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $111.66, for a total value of $1,116,600.00. Following the sale, the chief executive officer directly owned 591,203 shares of the company's stock, valued at approximately $66,013,726.98. This trade represents a 1.66% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 66,000 shares of company stock valued at $7,632,100. Company insiders own 0.27% of the company's stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $118.48 on Wednesday. The company has a market cap of $147.01 billion, a P/E ratio of 23.60, a P/E/G ratio of 0.80 and a beta of 0.34. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 52 week low of $84.80 and a 52 week high of $121.83. The business has a fifty day simple moving average of $114.84 and a 200-day simple moving average of $110.35.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same quarter in the previous year, the business earned $2.01 earnings per share. The firm's quarterly revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences's payout ratio is 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.